BCIQ Profiles

Company Profile Report
0601 Quick Takes
BioCentury & Getty Images

Regulation

June 1 Quick Takes: FDA approves Alkermes’ antipsychotic Lybalvi; plus Moderna, CTI, Akebia, Otsuka, Santhera

Jun 2, 2021 | 2:06 AM GMT

The quick response by Alkermes plc (NASDAQ:ALKS) to a November 2020 complete response letter for antipsychotic Lybalvi olanzapine/samidorphan has led to FDA’s approval of the drug to treat

Read the full 529 word article

How to gain access

Continue reading with a
two-week free trial.